Nutritional optimisation is fundamental
When to consult: warning signs and caution before any program Certain signs require medical attention: jaundice, persistent pain, unexplained weight loss, severe prolonged fatigue, significant digestive disorders, or rapid worsening
The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations

Moreover, mitochondria-targeted antioxidant MitoTEMPO (MT) treatment not only shielded the cells from mitochondrial damage after exposure of atorvastatin as a recovery of TMRM fluorescence intensity appeared in HCM (Figures 8C,D) and in C2C12 (Figures 8E,F) but also significantly prevented atorvastatin-induced myocyte death (Supplementary Figures S5A,B)
La profesora Helen M